Results 81 to 90 of about 39,211 (299)

Health economic considerations for pharmacogenomic services in the United Kingdom: The Centre for Excellence in Regulatory Science and Innovation in Pharmacogenomics

open access: yes
British Journal of Clinical Pharmacology, EarlyView.
Dyfrig A. Hughes   +4 more
wiley   +1 more source

Characterization of NAT2 Using Long‐Read Sequencing: Allele, Diplotype, and Phenotype Call Accuracy Compared to Other Testing Strategies

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
The NAT2 pharmacogene is essential in drug metabolism, particularly for aromatic amines and hydrazines. Genetic variations in NAT2 categorize individuals as rapid, intermediate, or poor metabolizers based on their acetylation capacity to inform dosing guidelines.
Shobana John   +4 more
wiley   +1 more source

Tramadol Co‐Administration with Oxycodone or Hydrocodone Increases Opioid Burden without Improving Postoperative Pain Control

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Tramadol is frequently co‐prescribed with oxycodone or hydrocodone after surgery under the assumption that its dual mechanism of action provides an opioid‐sparing benefit. However, evidence supporting this practice is limited and inconsistent. We conducted a secondary analysis of the multicenter IGNITE ADOPT‐PGx pragmatic trial of patients undergoing ...
Noor A. Nahid   +302 more
wiley   +1 more source

Pharmacogenomics of Myofascial Pain Syndrome

open access: yes, 2021
Current knowledge on the pharmacogenomics of myofascial pain ...
Jose Marie Lazaga
core   +1 more source

Dispensing of actionable pharmacogenetic drugs among adults receiving cardiovascular disease medications in the Northern Netherlands: A serial cross‐sectional study

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
The extent of pharmacogenetic (PGx) drug dispensing among Dutch adults receiving medications for cardiovascular disease (CVD) is unknown. Using the University of Groningen IADB.nl pharmacy database, we performed a serial cross‐sectional study (2019–2023) to estimate the annual prevalence of PGx drug dispensing and annual rates of initiation.
Zhuolin Zhang   +5 more
wiley   +1 more source

No Association Between Pharmacogenomics Variants and Hospital and Emergency Department Utilization: A Mayo Clinic Biobank Retrospective Study

open access: yesPharmacogenomics and Personalized Medicine, 2021
Paul Y Takahashi,1 Euijung Ryu,2 Suzette J Bielinski,3 Matthew Hathcock,2 Gregory D Jenkins,2 James R Cerhan,3 Janet E Olson3 1Division of Community Internal Medicine, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA; 2Division of ...
Takahashi PY   +6 more
doaj  

Pharmacogenomics landscape of COVID-19 therapy response in Serbian population and comparison with worldwide populations [PDF]

open access: yesJournal of Medical Biochemistry, 2020
Background: Since there are no certified therapeutics to treat COVID-19 patients, drug repurposing became important. With lack of time to test individual pharmacogenomics markers, population pharmacogenomics could be helpful in predicting a higher risk ...
Stanković Biljana   +7 more
doaj  

Pharmacogenomics Implementation Across Multiple Clinic Settings: A Qualitative Evaluation

open access: yes, 2023
Aim: To advance clinical adoption and implementation of pharmacogenomics (PGx) testing, barriers and facilitators to these efforts must be understood. This study identified and examined barriers and facilitators to active implementation of a PGx program ...
Rowe, Elizabeth   +7 more
core   +1 more source

Creatinine–Cystatin C Discrepancy and Renal Transporter Polymorphisms in Japanese Patients with Breast Cancer Receiving Abemaciclib

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Abemaciclib increases serum creatinine by inhibiting renal tubular transporters rather than reducing true glomerular filtration rate, a phenomenon known as pseudo‐acute kidney injury. Creatinine–cystatin C discrepancy and genetic determinants of this elevation remain insufficiently characterized in Japanese patients.
Hiroaki Watanabe   +5 more
wiley   +1 more source

Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC)

open access: yes, 2018
The P2Y12 receptor inhibitor clopidogrel is widely used in patients with acute coronary syndrome, percutaneous coronary intervention, or ischemic stroke.
International Clopidogrel Pharmacogenomics Consortium
core   +1 more source

Home - About - Disclaimer - Privacy